Price
No data yet.
Social Signal Score
Revenue
$21.00MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel J. Hicklin
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 39
- Beta
- 0.29
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -28.50
Financials
Revenue
$21.00M+406.3%Net Income
$3.67MEBITDA
$10.99MFree Cash Flow
$6.63MEPS (diluted)
$0.08Shares Outstanding (diluted)
48.60M+78.7%Operating Expenses
$13.84MCash & Debt
$21.99MReturn of Capital
$0.00Revenue by Segment (annual)
$1.89MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-60.82M | $-1.32 |
| 2024 | $1.89M | $-70.52M | $-1.63 |
| 2023 | $19.94M | $-37.37M | $-1.05 |
| 2022 | $16.40M | $-53.81M | $-1.86 |
| 2021 | $0.00 | $-49.98M | $-10.94 |
| 2020 | $0.00 | $-14.94M | $-0.98 |
| 2019 | $0.00 | $-10.99M | $-0.38 |
Valuation
HOWLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (2)
- Newsbenzinga.com·4h ago·Neutral
One of Israel Englander's Biotech Picks Just Turned Into a $500M Merger Story Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was one of the market's biggest pre-market movers on Friday after announcing a merger with Ambros Therapeutics.
View source ↗ - Newsglobenewswire.com·6h ago·Neutral
…ent and Concurrent Oversubscribed $150 million Private Placement WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., today announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Ambros Therapeutics' neridronate development program in Complex Regional Pain Syndrome Type 1 (“CRPS-1”, formerly known as Reflex…
View source ↗
Earnings
Tue, Nov 3(in 2 months)
Consensus estimate $-0.22 per share
Typical surprise +12.5% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Jul 31$0.08 vs $-0.28beat
- Thu, May 7$-0.28 vs $-0.32beat
- Fri, Mar 27$-0.20 vs $-0.34beat
- Tue, Nov 4$-0.36 vs $-0.39beat
- Thu, Aug 14$-0.40 vs $-0.50beat
- Thu, May 8$-0.40 vs $-0.44beat
Estimates and results for HOWL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HOWL officers and directors.
- Bought
- —
- Sold
- $3.6m
0 trades
95 trades
- Evnin Lukesold
- Evnin Lukesold
- Evnin Lukesold
- Ra Capital Management, L.p.sold
- Ra Capital Management, L.p.sold
- Ra Capital Management, L.p.sold
- Ra Capital Management, L.p.sold
- Ra Capital Management, L.p.sold
5 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.